|drug3482||Ultrasound of the lower limbs Wiki||0.71|
|drug1792||Linagliptin 5 MG Wiki||0.71|
|drug1827||Lovenox 40 MG in 0.4 mL Prefilled Syringe Wiki||0.71|
|D044882||Glucose Metabolism Disorders NIH||0.50|
|D008659||Metabolic Diseases NIH||0.41|
There are 2 clinical trials
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.
Description: Clinical change is defined as 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19: 0 - No clinical or virological evidence of infection; 1 - No limitation of activities; 2 - Limitation of activities; 3 - Hospitalized, no oxygen therapy; 4 - Oxygen by mask or nasal prongs; 5 - Non-invasive ventilation or high-flow oxygen; 6 - Intubation and mechanical ventilation; 7 - Ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation; 8 - Death.Measure: Time to clinical change Time: 28 days
Description: Percent of patients with a 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19.Measure: Percent of patients with clinical improvement. Time: 28 days
Coronavirus Disease-19 (COVID-19) is a global pandemics which affects many organs and systems with a range of morbidities and high mortality rates. There are a number of studies revealed that COVID-19 may affect the testes and male genital tract which may in turn disrupt the gonadal functions.The current study aimed to evaluate the effect of COVID-19 on semen parameters and sex-related hormone levels.
Description: cell count percentageMeasure: Semen analyses parameters including sperm motility (total, progressive, non-progressive and immotile Time: first 1 hour
Description: cell count per milliliters of semen sample.Measure: Semen analyses parameters including sperm concentration Time: first 1 hour
Description: percentage of normal formsMeasure: Semen analyses parameters including sperm morphology Time: first 1 hour
Description: millilitersMeasure: Semen analyses parameters including semen volume Time: first 1 hour
Description: nanograms per deciliterMeasure: Sex-related hormone levels including testosterone Time: 20 minutes
Description: Units per literMeasure: Sex-related hormone levels including follicle stimulating hormone and luteinizing hormone Time: 20 minutes
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports